Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In Lung Cancer

Lung Cancer for March/April 2019

Data From Routine Lung Cancer Visits Yield Research Insights,

Pembro Therapy Safe & Effective for Elderly Patients with NSCLC,

Tumor-Treating Fields Boost Chemo for Mesothelioma,

MET/MEK Inhibitor Duo Shows Activity in Resistant NSCLC,

Electromagnetic Navigation Bronchoscopy For Lung Lesion Biopsy,

More must reads

Lung Cancer for January/February 2019

NILE: Liquid biopsy bests tissue testing for targetable mutations in NSCLC,

Caring for aging HIV-infected patients requires close attention to unrelated diseases,

SABR response rate falls short in early NSCLC,

More must reads

Lung Cancer for November/December 2018

Lenvatinib plus pembrolizumab shows promising activity in NSCLC, Brose M et al. SITC 2018, Abstract P392

NGS may ID SCLC candidates for immunotherapy, SITC 2018
More must reads

Lung Cancer for September/October 2018

Prophylactic cranial irradiation boosts OS in advanced NSCLC , Arrieta O et al. WCLC 2018, Abstract MA08.02.

Nivolumab safe and effective for cancer patients with HIV, Gobert et al. ESMO 2018, Abstract 1213P_PR.

Alectinib demonstrates better CNS efficacy in ALK+ NSCLC, Gadgeel SM et al. Ann Oncol. 2018 Sep 12. doi: 10.1093/annonc/mdy405

CT scans cut lung cancer deaths, A presentation at the World Conference on Lung Cancer

Baseline steroid use may decrease efficacy of checkpoint inhibitors, Arbour KC et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.79.0006.
More must reads

Lung Cancer for July/August 2018

Promise of broad genomic testing of NSCLC disappoints in community oncology , Presley CJ et al. JAMA. 2018 Aug 7. doi: 10.1001/jama.2018.9824

Clinical utility of rapid EFGR testing for patients with NSCLC, Dagogo-Jack I et al. JCO Precis Oncol. 2018 Jul 24. doi: 10.1200/PO.17.00299.
More must reads

Pages